Assay method for single-chain urokinase-type plasminogen activator. 1989

O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
Department of Physiology, Kinki University School of Medicine, Osakasayama, Japan.

A new assay method for measuring single-chain urokinase-type plasminogen activator (scu-PA) activity by quantitative calorimetric assay method is described. The serine enzyme u-PA activates plasminogen to plasmin, and scu-PA is a precursor protein obtained from a tissue culture of human kidney cells. The scu-PA solution was activated by plasmin to two-chain u-PA, which releases p-nitroaniline from pyro-Glu-Gly-Arg-pNA, and the optical density at 405 nm was measured. One unit of scu-PA was defined on the basis of 1 nmol of p-nitroaniline released from the substrate per second. One unit of scu-PA was found to be equivalent to 335 u-PA (two-chain) units (IU).

UI MeSH Term Description Entries
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010960 Plasminogen Activators A heterogeneous group of proteolytic enzymes that convert PLASMINOGEN to FIBRINOLYSIN. They are concentrated in the lysosomes of most cells and in the vascular endothelium, particularly in the vessels of the microcirculation. Extrinsic Plasminogen Activators,Plasminogen Activator,Uterine-Tissue Plasminogen Activator,Uterine Tissue Plasminogen Activator
D002151 Calorimetry The measurement of the quantity of heat involved in various processes, such as chemical reactions, changes of state, and formations of solutions, or in the determination of the heat capacities of substances. The fundamental unit of measurement is the joule or the calorie (4.184 joules). (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005341 Fibrinolysin A product of the lysis of plasminogen (profibrinolysin) by PLASMINOGEN activators. It is composed of two polypeptide chains, light (B) and heavy (A), with a molecular weight of 75,000. It is the major proteolytic enzyme involved in blood clot retraction or the lysis of fibrin and quickly inactivated by antiplasmins. Plasmin,Fibrogammin,Glu-Plasmin,Protease F,Thrombolysin,Glu Plasmin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator

Related Publications

O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
November 1996, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
December 1995, International journal of cancer,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
July 1987, The Journal of pharmacology and experimental therapeutics,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
December 1987, European journal of biochemistry,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
October 1991, Gene,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
October 2023, The Journal of biological chemistry,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
August 1995, The Journal of biological chemistry,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
May 1988, The American journal of cardiology,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
January 1986, Cold Spring Harbor symposia on quantitative biology,
O Matsuo, and S Ueshima, and K Okada, and H Fukao, and M Ohgaki, and R Watanabe, and H Arimura
June 1991, Biochemistry,
Copied contents to your clipboard!